|
Oct 10
|
BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
|
|
Jul 29
|
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
|
|
Jun 18
|
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
|
|
Jun 17
|
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
|
|
Apr 10
|
BioPorto A/S Appoints Chief Legal Officer
|
|
Jan 9
|
BioPorto implements changes to the Executive Management.
|
|
Dec 9
|
Managers’ transactions
|
|
Dec 8
|
FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)
|
|
Dec 7
|
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
|
|
Dec 4
|
Resignation of Director
|
|
Aug 28
|
BioPorto to Participate in Upcoming Investor Conferences
|